ANRO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
27.2M
-6.5%
29.1M
+7.3%
27.1M
+59.1%
17.1M
+14.1%
15.0M
R&D
18.2M
-17.9%
22.1M
+8.9%
20.3M
+69.2%
12.0M
+14.0%
10.5M
SG&A
9.1M
+29.1%
7.0M
+2.6%
6.8M
+35.3%
5.1M
+14.3%
4.4M
Operating Income
-27225000
+6.5%
-29129000
-7.3%
-27138000
-59.1%
-17055000
-14.1%
-14951000
EBITDA
-27044000
+6.6%
-28945000
-7.4%
-26954000
-59.5%
-16898000
-14.3%
-14787000
Net Income
-25124000
+9.1%
-27638000
-5.3%
-26237000
-62.1%
-16182000
-14.1%
-14181000
EPS (Basic)
$-0.54
+16.9%
$-0.65
+18.8%
$-0.80
-70.2%
$-0.47
+9.6%
$-0.52
EPS (Diluted)
$-0.54
+16.9%
$-0.65
+18.8%
$-0.80
-70.2%
$-0.47
+9.6%
$-0.52
Shares (Diluted)
46.5M
+8.7%
42.8M
+30.2%
32.9M
-3.8%
34.2M
+26.1%
27.1M
Alto Neuroscience (ANRO) — Financials